Bi-layer Wound Dressings Achieving Rapid Hemostasis and Antibacterial Protection with Tranexamic Acid and Nitric Oxide

Study Background and Research Question

Uncontrolled hemorrhage and infection are the leading causes of morbidity and mortality in trauma patients, accounting for a substantial proportion of deaths in both civilian and combat-related injuries. Despite advances in wound care, achieving rapid, reliable hemostasis while simultaneously preventing infection remains a considerable challenge, especially in emergency or battlefield settings. Nitric oxide (NO) is recognized for its multifaceted roles in wound healing, including its antibacterial, anti-inflammatory, and tissue-regenerative effects. Tranexamic acid (TXA), a synthetic antifibrinolytic agent, is clinically established for reducing bleeding by inhibiting fibrinolysis. The reference study sought to address the dual challenge of hemorrhagic control and infection prevention by engineering a wound dressing that integrates the hemostatic and antimicrobial benefits of these agents in a single, deployable system (see internal analysis).

Key Innovation from the Reference Study

The central innovation of the referenced work (Nguyen et al.) is the development of a bi-layer wound dressing designed for instant clot formation and robust antibacterial activity. The design combines three functional components:

• Tranexamic acid (TXA): Suspended in a resinous bed of propolis, positioned adjacent to the wound, providing localized inhibition of fibrinolysis and promoting stable clot formation.
• Propolis: A natural bioadhesive with intrinsic antibacterial and anti-inflammatory properties, serving as a carrier matrix for TXA.
• S-nitroso-N-acetylpenicillamine (SNAP): An NO donor embedded in a Carbosil® polymer layer, gradually releasing nitric oxide to support antibacterial and wound-healing effects.

This bi-layer configuration allows for both immediate hemostasis via antifibrinolytic action and sustained antibacterial protection, addressing key unmet needs in trauma wound management.

Methods and Experimental Design Insights

The wound dressing, termed T-SP (TXA–SNAP–propolis), was constructed with a strategic bi-layer architecture. The wound-facing layer consisted of TXA immobilized within propolis, formulated at varying concentrations (2.5%, 5.0%, and 7.5% vol/vol propolis). The base layer, containing SNAP in a Carbosil® matrix, was situated distal to the wound interface. Key methodological points include:

• Platelet adhesion assay: A lactate dehydrogenase-based assay quantified fibrin activation and clot stability within 15 minutes of dressing application.
• Scanning electron microscopy (SEM): Used to visualize the fibrin network at the wound interface, confirming the formation of a dense, stable clot.
• Antibacterial testing: Assessed the reduction in colony-forming units (CFU) for Staphylococcus aureus and multidrug-resistant Acinetobacter baumannii upon exposure to the dressing.

This experimental design enabled a direct comparison of hemostatic and antibacterial efficacy across different propolis concentrations and provided mechanistic insights into the interaction between antifibrinolytic and antimicrobial components.

Core Findings and Why They Matter

The study reported several notable outcomes (Nguyen et al.):

• Enhanced Hemostasis: The 7.5% propolis T-SP dressing showed significantly increased fibrin activation compared to control within 15 minutes, as measured by platelet adhesion assays. SEM imaging revealed a robust fibrin matrix, indicating successful stabilization of the clot.
• Potent Antibacterial Activity: NO release from SNAP and the presence of propolis led to a 98.9 ± 1% reduction in S. aureus and a 99.4 ± 1% reduction in A. baumannii CFUs, demonstrating the dressing's efficacy against both common and multidrug-resistant bacteria.
• Synergistic Mechanisms: The combination of antifibrinolytic and antimicrobial agents in a layered format allowed rapid hemostasis without compromising antibacterial protection, an advance over current single-function dressings.

These findings are significant for translational wound care, highlighting the potential for integrated biomaterials to address the dual threats of bleeding and infection—especially in acute trauma scenarios where time and resources are limited.

Comparison with Existing Internal Articles

The reference study's approach builds upon established mechanistic insights into tranexamic acid's role as an antifibrinolytic agent. As summarized in the article "Tranexamic Acid: Mechanistic Insights for Advanced Fibrinolysis Research", TXA acts by competitively inhibiting plasminogen activation, thereby stabilizing clots—a mechanism exploited in the T-SP dressing. Other internal resources, such as "Tranexamic Acid: Antifibrinolytic Agent for Hemostasis Research", also highlight TXA's utility in reducing bleeding time and its established use in translational wound models. The novel contribution of the present study lies in the integration of TXA with propolis and a nitric oxide donor, delivering both rapid clot formation and antibacterial action in a deployable dressing—a synergy not previously demonstrated in the reviewed internal articles.

Limitations and Transferability

While the T-SP dressing demonstrates promising efficacy in vitro, several limitations must be considered before clinical translation:

• Model limitations: The study primarily assessed clot formation and antibacterial effects in controlled laboratory settings, which may not fully replicate the complexity of human traumatic wounds.
• Long-term outcomes: The durability of the dressing, potential cytotoxicity from NO release, and the impact on long-term wound healing were not extensively evaluated.
• Manufacturing scalability: The feasibility of large-scale production and regulatory compliance for combined bioactive dressings remains to be established.

Nevertheless, the layered design offers a versatile platform for further optimization, and the mechanisms demonstrated are relevant for researchers developing next-generation wound care materials.

Protocol Parameters

• Propolis concentration: 2.5–7.5% (v/v) in the TXA-resin layer; higher concentrations (7.5%) yielded greater fibrin activation.
• Tranexamic acid loading: Uniform dispersion in the wound-contacting layer; recommended to match the reference dressing’s TXA:propolis ratio for reproducibility.
• NO donor (SNAP) loading: Embedded within Carbosil® polymer base layer; gradual release profile suggested for sustained antibacterial effect.
• Platelet adhesion assay: Quantify clot formation 15 minutes post-application using a lactate dehydrogenase-based readout.
• Antibacterial efficacy: Test against both Gram-positive and multidrug-resistant Gram-negative strains to assess spectrum of activity.

Research Support Resources

For researchers aiming to replicate or extend these workflows, high-quality reagents are essential. Tranexamic Acid (SKU B1858) is available from APExBIO as a high-purity antifibrinolytic agent, with detailed characterization and workflow guidance. Its well-documented properties—including plasmin inhibition and support for clot stability—make it suitable for advanced fibrinolysis and wound modeling studies. When designing instant clot-forming or antibacterial dressings, ensure that antifibrinolytic agents are used at concentrations and in matrices consistent with the referenced protocols for optimal reproducibility and translational relevance.